<scp>BRAF V600E</scp> protect from cell death via inhibition of the mitochondrial permeability transition in papillary and anaplastic thyroid cancers-Reference-Cited by-同舟云学术

BRAF V600E protect from cell death via inhibition of the mitochondrial permeability transition in papillary and anaplastic thyroid cancers

Published:2022-06-24 Issue:14 Volume:26 Page:4048-4060
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cellular Molecular Medi

Author:

Gao Yanyan¹²^ORCID,Zhang Deyu¹,Wang Fei¹,Zhang Dejiu¹,Li Peifeng¹,Wang Kun¹

Affiliation:

1. Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine Qingdao University Qingdao China

2. Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine Jiangsu Institute of Nuclear Medicine Wuxi China

Funder

China Postdoctoral Science Foundation

National Natural Science Foundation of China

Natural Science Foundation of Jiangsu Province

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.17443

Reference50 articles.

1. Presencia de la mutación BRAFT1799A en el tumor primario como indicador de riesgo, recidiva o persistencia de carcinoma papilar de tiroides

2. Distinct Clinical and Pathological Features Are Associated with the BRAFT1799A(V600E) Mutation in Primary Melanoma

3. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma

4. Mutations of the BRAF gene in human cancer

5. BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review;Critical Reviews in Oncology/Hematology;2024-11

2. Di- and Triselenoesters—Promising Drug Candidates for the Future Therapy of Triple-Negative Breast Cancer;International Journal of Molecular Sciences;2024-07-16

3. Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy;Cell Communication and Signaling;2024-07-15

4. Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma;Cell Death Discovery;2024-04-15

5. Mechanisms of vemurafenib-induced anti-tumor effects in ATC FRO cells;Heliyon;2024-03